News Gilead cleared to restart trials of CD47 drug magrolimab Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion
News Pfizer vaults into CD47 arena, buying Trillium for $2.3 bill... Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.
Events Partner Content 2nd Macrophage-directed Therapies Summit Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK